Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Mallinckrodt plc (MNK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 22, 2015.
Market data for MNK model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for MNK.
Model is being retrained on a daily basis.
| Float | 85M |
| P/E | 1.73 |
| Shares Outstanding | 86M |
| % Held by Insiders | 1.80% |
| % Held by Institutions | NaN% |
| EPS (last reported FY) | $7.49 |
| EPS (last reported Q) | $2.01 |
| EPS, estimated (last reported Q) | $1.72 |
| Total revenues | $3 B |
| Net income | $2 B |